Date & Time
March 10, 2026, 5 p.m. - March 10, 2026, 7 p.m.
Cost
$0
Location
BioSpark Labs
380 Michel St Suite A
Atlanta, GA, 30313
March 10, 2026, 5 p.m. - March 10, 2026, 7 p.m.
$0
BioSpark Labs
380 Michel St Suite A
Atlanta, GA, 30313
University Bioconnect is a biotech meetup group based in Atlanta that aims to build community among the many world-class life sciences researchers.
BioSpark Labs offers laboratory and office space in Science Square, the center of Atlanta’s biotech ecosystem. Companies can lease bench space, private labs, or office suites with flexible terms and gain access to advanced in-house research equipment, vendor discounts, and a collaborative community closely connected to Georgia Tech.
We're excited to welcome Gabe Kwong, Ph.D., Associate Professor and Wallace H. Coulter Distinguished Faculty Fellow in the Department of Biomedical Engineering at Georgia Tech and Emory. He earned his B.S. in Bioengineering with Highest Honors from the University of California at Berkeley, his Ph.D. from Caltech, and conducted postdoctoral studies at MIT. Dr. Kwong directs the Laboratory for Synthetic Immunity, where he leads a multidisciplinary team focused on engineering cell therapies and immune sensors for early detection. His research impacts broad arenas in biomedicine including cancer, transplantation medicine, and infectious diseases. His work is published in leading scientific journals and profiled broadly, including coverage in The Economist, NPR, BBC, and WGBH-2, Boston’s PBS station.
In recognition of his work, Dr. Kwong was named a "Future Leader in Cancer Research and Translational Medicine" by the Massachusetts General Hospital and selected by the National Academy of Engineering for the US Frontiers of Engineering. His list of distinctions includes the Burroughs Wellcome Fund Career Award at the Scientific Interface, NIH Director's New Innovator Award, TEDMED Hive Innovator Award, and the SBUR Don Coffey Lectureship. Dr. Kwong is co-founder of Glympse Bioand Port Therapeutics, which have combined to raise over $85+million in capital, with several products undergoing clinical evaluation. He holds over 25 issued or pending patents in biotechnology.